Search results
Added:
3 years ago
Hypertension is a common and serious problem that is the major cause of morbidity and mortality worldwide.1–3 Over 70 million people in the US are affected by high blood pressure (BP) that requires treatment, and nearly one-third of the adult population in the US have a BP of ≥140/90mmHg, which is the defined cut-off value for hypertension.2,4 It is estimated that over 44% of people in Europe are…
View more
Added:
3 years ago
Hypertension is the most common chronic disease in the US, affecting 29% of the adult population.1 Once considered a benign, compensatory mechanism for ageing, high blood pressure (BP) is now recognised as an important risk factor for cardiovascular disease. It is estimated that inadequate BP control is responsible for 62% of cases of cerebrovascular disease, 49% of cases of ischemic heart…
View more
Added:
3 years ago
Distinct hypertensive syndromes causing drug-resistant hypertension are increasingly being recognised. The ability to recognise these disorders has come as a result of a better understanding of their pathogenesis and the availability of sensitive and accurate diagnostic tools. The particular appeal of making the diagnosis centres around the potential curability of the hypertension, with…
View more
Added:
3 years ago
High blood pressure is the major risk factor for disease and premature death worldwide.1 The associations between blood pressure and fatal coronary artery disease and fatal stroke have been well demonstrated.2 Also, associations between blood pressure and morbidity and mortality on specific cardiovascular disease conditions in different age groups, and results concerning the lifetime risk for…
View more
Added:
3 years ago
The concept of resistant hypertension (RH) has received great attention in the past years, mainly as a possible target population for innovative therapeutic strategies. An increasing number of original articles and commentaries have focused on the clinical significance, prognosis and treatment of this condition. Thus it is not surprising than even its definition is still a matter of debate,…
View more
Added:
3 years ago
Recent guidelines have defined resistant hypertension (RHT) as blood pressure (BP) that does not fall below 140/90 mmHg, despite a therapeutic strategy that includes appropriate lifestyle measures, plus a diuretic and two other antihypertensive drugs belonging to different classes at adequate doses.1 The definition of RHT has been quite arbitrary, a fact reflected on various definitions of ideal…
View more
Added:
1 year ago
AHA 2022 — Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial (NCT03541174).This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan (Idorsia Pharmaceuticals Ltd.) in resistant hypertension.
Presented first at AHA 22, the trial showed that…
View more
Added:
2 years ago
In this short summary interview, Dr. Ajay Kirtane (Columbia University Medical Center, US) shares the six-month outcomes of a randomized trial of renal denervation (RDN) versus a sham procedure for resistant hypertension. The RADIANCE-TRIO Trial, presented first at TCT 2021, showed that the additional effects of pharmacologic intervention with maintenance of a BP-lowering effect of endovascular…
View more
Added:
3 years ago
Renal sympathetic denervation (RDN) has been introduced as a novel approach to treat patients with so-called resistant hypertension.1–3 The first randomised clinical trial showed an impressive 32/12 mmHg fall in blood pressure after six months in the intervention group (n=52) compared to the control group (n=54). However, with the recent publication of the Symplicity HTN-3 study in the US4 the…
View more
